The9 Limited faces a precarious outlook as its strategic pivot into digital asset mining has failed to yield sustainable profitability, evidenced by a 75.7% year-over-year revenue contraction in 2024Q4. The company's reliance on significant stock-based compens...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 24, 2026 | $3.00 vs — | $13M vs — |
Q2 2026 Apr 27, 2026 | -$3.06 vs — | $6M vs — |
Q2 2025 Apr 21, 2025 | -$1.97 vs — | $3M vs — |
Q2 2024 May 6, 2024 | $0.04 vs — | $12M vs — |
The9 NASDAQ: NCTY reported second-quarter net income of $32 million, up more than 39% from the prior quarter, as the company advanced its repositioning around The9bit, an AI-powered game creation platform supported by a token-based ecosystem.
Increase driven by the fair-value recognition of 9BIT tokens received under the Company's cooperation agreement with the 9BIT Foundation as the9bit continued to expand AI capabilities, community engagement and commercial partnerships SHANGHAI, Aug. 24, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today reported its unaudited financial results for the three months ended June 30, 2026. Second Quarter 2026 Highlights Strong sequential growth: Net income for the quarter was US$32 million, an increase of more than 39% from the previous quarter.
The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting
Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed Company SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step toward its planned Nasdaq listing.
Benchmark NCTY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for The9 Limited (NCTY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.02 | $18.8M | -0.53 | -4.77% | -372.99% | -120.1% | — | |
| $12.84 | $385.89M | 0.92 | -2.35% | 38.09% | 18.67% | — | |
| $69.61 | $483.71M | 9.72 | 11.92% | 13.11% | 9.3% | — | |
| $117.47 | $75B | 15.06 | 6.96% | 27.89% | 19.48% | — | |
| $1.32 | $14.59M | -9.43 | 17.01% | -52.03% | -4.62% | — | |
| $15.18 | $6.37B | 39.25 | 13.1% | 2.14% | 4.39% | — |
The9 Limited (NCTY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NCTY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The9 Limited (NCTY) stock FAQ — growth, dividends, profitability & financials explained
The9 Limited (NCTY) reported $212.4M in revenue for fiscal year 2025. This represents a 3742% increase from $5.5M in 2001.
The9 Limited (NCTY) saw revenue decline by 4.8% over the past year.
Yes, The9 Limited (NCTY) is profitable, generating $592.8M in net income for fiscal year 2025 (-373.0% net margin).
The9 Limited (NCTY) has a return on equity (ROE) of -120.1%. Negative ROE indicates the company is unprofitable.
The9 Limited (NCTY) had negative free cash flow of $90.5M in fiscal year 2025, likely due to heavy capital investments.
